Short-Term Benefits for Immunotherapy in Allergic Asthma

Reductions seen in short-term symptom scores and medication scores, with evidence of publication bias

asthma inhaler

FRIDAY, June 2, 2017 (HealthDay News) -- Administration of allergen immunotherapy (AIT) in patients with allergic asthma leads to lower short-term symptom and medication scores, according to a review published online May 19 in Allergy.

Sangeeta Dhami, M.B.B.S., from Evidence-Based Health Care in Edinburgh, U.K., and colleagues performed a systematic review to examine evidence on the effectiveness, cost-effectiveness, and safety of AIT. Data were reviewed from 98 studies.

The researchers observed a reduction in short-term symptom and medication scores, with evidence found for publication bias. No reduction was seen in short-term combined medication and symptom scores; a beneficial long-term effect was seen in one study. Subcutaneous immunotherapy correlated with improved quality of life and reduction in allergen-specific airway hyperreactivity (AHR); this was not seen for sublingual immunotherapy (SLIT). No consistent effects were seen on asthma control, exacerbations, lung function, or non-specific AHR. There was a modest increase in the risk of adverse events with AIT. Evidence on cost-effectiveness was mainly available for SLIT, which was likely to be cost-effective.

"AIT can achieve substantial reductions in short-term symptom and medication scores in allergic asthma," the authors write. "More data are needed in relation to secondary outcomes, longer-term effectiveness, and cost-effectiveness."

Several authors disclosed financial ties to the biopharmaceutical industry.

Full Text

Physician’s Briefing Staff

Physician’s Briefing Staff

Updated on June 02, 2017

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ